The relationships between blood levels of estrogen and lipoprotein lipids and apoproteins were evaluated in 120 women early in the climacteric. Among women who were 1-year amenorrheic, not taking hormone replacement therapy, and with follicle-stimulating hormone levels >720 ng/ml, serum estradioi levels were positively related to concentrations of the high density lipoprotein 2 cholesterol (HDL 2 c) subfraction. There was a substantial decrease in HDL 2 c and apoprotein (apo) A-l in women whose estradioi levels decreased to <2.5 pg/ml from the first to the second postmenopausal examination. In a sample of women evaluated during the perimenopause (3-months' amenorrheic), those with the highest concentrations of estradioi or estrone showed a (nonsignificantly) higher level of HDL 2 c and a lower level of low density lipoprotein cholesterol (LDLc) than did those with the lowest concentration of estradioi or estrone. Estradioi levels declined dramatically between the perimenopausal and the postmenopausal examinations, and this was accompanied by a decrease in HDL 2 c and a nonsignificant increase in LDLc. HDL 2 c levels fell substantially in those women whose estradioi decreased below the sensitivity of the assay. The change, however, was not statistically significant. Estrone is the primary postmenopausal estrogen, and levels are directly related to obesity, as are levels of insulin. The interrelationship among obesity, conversion of estrone to estradioi at the tissue level, and insulin (or insulin sensitivity) is probably the primary determinant of HDLc concentration among postmenopausal women. (Arteriosclerosis 10:1058-1066, November/December 1990) A higher level of high density lipoprotein cholesterol (HDLc) in women is probably a major reason for their lower coronary heart disease (CHD) incidence and mortality as compared to men. Decreased ovarian estrogen synthesis, such as occurs after bilateral oophorectomy, has been related to an increased risk of myocardial infarction 1 and, possibly, of the extent of coronary atherosclerosis.
The relationships between blood levels of estrogen and lipoprotein lipids and apoproteins were evaluated in 120 women early in the climacteric. Among women who were 1-year amenorrheic, not taking hormone replacement therapy, and with follicle-stimulating hormone levels >720 ng/ml, serum estradioi levels were positively related to concentrations of the high density lipoprotein 2 cholesterol (HDL 2 c) subfraction. There was a substantial decrease in HDL 2 c and apoprotein (apo) A-l in women whose estradioi levels decreased to <2.5 pg/ml from the first to the second postmenopausal examination. In a sample of women evaluated during the perimenopause (3-months' amenorrheic), those with the highest concentrations of estradioi or estrone showed a (nonsignificantly) higher level of HDL 2 c and a lower level of low density lipoprotein cholesterol (LDLc) than did those with the lowest concentration of estradioi or estrone. Estradioi levels declined dramatically between the perimenopausal and the postmenopausal examinations, and this was accompanied by a decrease in HDL 2 c and a nonsignificant increase in LDLc. HDL 2 c levels fell substantially in those women whose estradioi decreased below the sensitivity of the assay. The change, however, was not statistically significant. Estrone is the primary postmenopausal estrogen, and levels are directly related to obesity, as are levels of insulin. The interrelationship among obesity, conversion of estrone to estradioi at the tissue level, and insulin (or insulin sensitivity) is probably the primary determinant of HDLc concentration among postmenopausal women. (Arteriosclerosis 10:1058-1066, November/December 1990) A higher level of high density lipoprotein cholesterol (HDLc) in women is probably a major reason for their lower coronary heart disease (CHD) incidence and mortality as compared to men. Decreased ovarian estrogen synthesis, such as occurs after bilateral oophorectomy, has been related to an increased risk of myocardial infarction 1 and, possibly, of the extent of coronary atherosclerosis. 2 An increased risk of myocardial infarction or CHD death after natural menopause has also been reported. Oral exogenous estrogen therapy raises the level of HDLc, as well as the HDL 2 c and HDL 3 c subtractions. The reported decreased CHD risk among women taking estrogen replacement therapy has been partially attributed to an increase in HDLc levels. 3 Higher estrogen levels during pregnancy among primates have been associated with a subsequent decrease in the extent of coronary atherosclerosis at postmortem examinations. 4 An association between endogenous sex steroid hormones and lipoprotein levels has not been thoroughly evaluated, and the evidence does not point to a simple relationship. Most cross-sectional studies have not demonstrated a decline in HDLc among older women as compared with younger women. 56 Oophorectomy has been reported to result in an increase in total cholesterol and triglyceride levels, but in relatively little change in HDLc or apolipoprotein (apo) A-l. 7 Luteinizing hormone (LH) releasing hormone (RH) agonists substantially decrease folliclestimulating hormone (FSH) and LH levels and, consequently, blood estrogen from pre-to postmenopausal levels. 8 At least one recent study has noted that LH RH agonists do not result in a decrease in HDLc in spite of a substantial reduction in blood estrogen levels. 8 Women taking Danazol, a weak androgen, showed substantially decreased FSH, LH, and serum estrogen levels, with an increase in LDLc and a decrease in HDLc, especially the HDL 2 c subfraction. 9 These effects are similar to those produced by the ingestion of 19 nortestosterone drugs. 10 Howard et al. 11 recently reported a significant correlation between blood estradioi levels and HDL 2 c concentrations among premenopausal Pima Indian women.
In the present study, we examined the relationship between endogenous levels of estradioi, estrone, and lipoproteins after 12 months of amenorrhea. We tested the hypothesis that there is a relationship between the levels of HDLc and its subtractions, HDL 2 c and HDUc and the blood levels of estradioi and estrone among women in the early postmenopausal period.
women living in Pittsburgh, Pennsylvania, randomly selected from driver's license lists 12 who were premenopausal and ages 42 to 50 at baseline. The study was approved by the Biomedical Institutional Review Board of the University of Pittsburgh. The women were not taking hormone therapy at entry into the study and had not undergone hysterectomy or bilateral oophorectomy. Other exclusion criteria included treated hypertension, thyroid disease, and diabetes mellitus. Baseline examinations were conducted between November 1983 and May 1985 and included measures of age, alcohol intake, cigarette smoking, physical activity, height, weight, and (in a subsample) waist-to-hip ratio. The detailed laboratory methods have previously been described. 12 The women fasted for 12 hours before a venipuncture for measurement of lipoprotein lipids, apoproteins, and triglycerides. Using sera, high density lipoprotein cholesterol (HDLc) was measured by a heparin-manganese precipitation procedure. The HDLc subfraction, HDL 2 c, forms a precipitate after addition of dextran sulfate to the supernatant obtained with heparin-manganese chloride. The cholesterol content of the supernatant was measured, and the concentration of HDL 2 c was found by subtracting HDL 3 c from the concentration of total HDLc. Triglycerides were determined enzymatically, and low density lipoprotein cholesterol (LDLc) was calculated by using the Friedewald formula.
Serum samples (5 ml) for apoprotein determinations were frozen at -70°C for up to 3 months before overnight shipment on dry ice to the laboratory. Apo A-l and B were assayed by electroimmunoassay. The intra-assay coefficient of variation for apo A-l was 6.7% at a mean concentration of 139 mg/dl, and for apo B it was 9.9% (mean=106 mg/dl). An enzyme-linked immunoadsorbent assay was used to determine the apo A-ll levels. The intra-assay coefficient of variation for apo A-ll was 7.1% (mean=31 mg/dl).
After the baseline examination, women completed and returned monthly postcards with information about their menstrual status. After 12 months' amenorrhea, the women were scheduled for postmenopausal examinations identical to their baseline evaluations. FSH and LH, as well as the total serum estradiol and estrone, were measured. An FSH level above 720 ng/ml was considered to be characteristic of postmenopausal status in the women who had been amenorrheic for at least 12 months. 13 The estrogen concentrations, estrone and estradiol, were measured by highly specific methods involving extraction, column chromatography, and radioimmunoassay by use of a specific antibody from sheep. During the extraction step, a small amount of radioactive ( 3 H) steroid was added to each sample to correct for procedural losses during extraction and subsequent chromatography. The purpose of the extraction step is to transfer the steroid hormone from an aqueous phase in the plasma to an organic phase (carbon tetrachloride) in which it is very soluble. The chromatography step separates the hormone from other similar hormones and increases the specificity of the assay system. A "specific antibody" radioimmunoassay is only specific for those compounds that have been checked for cross-reactivity. The within-assay variation was 10%, while the between-assay variation was 15% for estrone. For estradiol, the within-assay variation was 8% and the between-assay variation was 10%. For individuals whose hormone levels were found to be below the sensitivity level of the assay (2.5 pg/ml), the sensitivity level was used in the analyses. 14 We had previously evaluated the short-and long-term variability of sex steroid hormone measurements in the same laboratory. Short-term variability was evaluated by having blood drawn from nine postmenopausal women at half-hour intervals. The results showed the intra-individual correlation for estrone to be 0.89 and for estradiol to be 0.66. Blood samples were drawn again 4 weeks later, with a resulting intra-individual correlation over 1 month of 0.72 for estrone and 0.45 for estradiol. The variability over 3 years was evaluated among 174 older postmenopausal women; the intra-individual correlation for this group was 0.56 for estrone and 0.36 for estradiol. The variability of estrone was similar to that for HDL 2 c, HDL3C, and systolic or diastolic blood pressure over 3 years. A frozen, stored aliquot was analyzed in the laboratory along with each batch of hormones measured to serve as a control for evaluation of the effects of long-term freezing and laboratory drift. There was no evidence of laboratory drift nor any effect of long-term freezing at -70°C.
14 Some baseline and follow-up results from this study have been published. 1516 At baseline, the mean age of the women was 47 years, 75% had some college education, and 9% (n=48) were black. The mean values (mg/dl) were total cholesterol=184, HDLc=59.3, HDL 2 c= 20.8, HDI-3C=38.5, LDLc=108, fasting triglycerides= 83.7, apo A-l = 143, apo A-ll=52.3, and apo B=93.6. The mean body mass index (BMI) (weight over height squared) was 24.8. Approximately 70% of the women were nonsmokers at entry, and 34% reported at least one drink of alcohol per week. The women reported expending an average of 1453 kilocalories of physical activity per week, and they reported consuming 30% of their calories from fat. The primary determinants of HDLc and subfraction levels were alcohol intake, physical activity, cigarette smoking, and BMI.
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Sample Description
As of March 11, 1989 , 210 women had become menopausal; 72 of these women were taking hormone replacement therapy and were excluded from further analysis. There were no significant differences in the levels of baseline lipoproteins or apoproteins between women who were prescribed therapy and those who were not. Of the remaining 138 menopausal women, blood samples were available for measurement of estrone in 120 and for estradiol in 99. Estradiol was not measured in 21 women because of an inadequate amount of serum for doing the analysis. Women who did not have blood specimens for any hormone measurements either did not come in for an examination or refused the venipuncture. Six women came in for their examination and had measurements of hormones after the cutoff point for data analyses.
The 120 women for whom blood samples were available became menopausal between February 1985 and March 1989. Three women had levels of estradiol >100 pg/ml or estrone >200 pg/ml and were eliminated 'Includes three women with estradioi >100 pg/ml. flncludes one woman with estrone >200 pg/ml.
LDLc=low density lipoprotein cholesterol, HDLc=high density lipoprotein cholesterol, apo=apolipoprotein, BMI=body mass index, SE=standard error.
from the analyses of hormones and risk factors. The initial blood samples were obtained after about 12 months of amenorrhea. FSH levels were available for 114 of the 120 women and averaged 1996 ng/ml, with a minimum of 234 and a maximum of 4616. Only four of the 120 women had FSH levels below 720 ng/ml, the lower limit consistent with postmenopausal status. 13 These four were retained for the analysis because the definition of menopause was 12-months' amenorrhea. Their inclusion does not alter the results.
Analyses
Nonparametric correlation coefficients (Spearman's rho) were calculated between the estrogen and lipoprotein levels and the other factors. Estrogen levels were grouped into quintiles with the exception of the lowest group, which included the lowest quintile plus all values below the sensitivity of the assay. The nonparametric Kruskal-Wallis test was used to test for significant differences in medians for lipoproteins and other factors according to the grouping of estrogen level. Multiple regression analysis was used to evaluate the relationship between the hormones, other risk factors, and the lipoprotein levels.
Results
The distribution of the baseline characteristics among the 120 women who had estrogen measurements at the first postmenopausal examination is shown in Table 1 .
We first evaluated the relationship between estrone and estradioi and selected variables that might affect hormone levels. The median FSH differed significantly between the estradioi quintiles (p=0.004, nonparametric analysis of variance), with generally lower FSH levels at higher estradioi levels ( Figure 1 ). Only one woman in the highest quintile of estradioi had an FSH level <720 ng/ml.
The inverse relationship between FSH and estradioi levels was consistent with some ovarian estrogen production. There was no relationship between estrone and FSH levels. Estrone is likely to be mainly derived from aromatization of androstenedione.
Levels of both estrone and estradioi were inversely correlated with age (Spearman's rho) at the time of the menopause. Lipoprotein levels were not related to the duration of amenorrhea. BMI was positively, but not significantly, correlated with levels of estradioi (rho=0.07, p=0.26) and estrone (rho=0.12, p=0.10). The waist-to-hip ratio was not correlated with estrone (rho= -0.05, p=0.3) or estradioi (rho=-0.06, p=0.3). Physical activity measured as kilocalories expended per week was not related to estradioi level, but was significantly correlated with estrone (rho=-0.18, p=0.03). There was no relationship between estrogen levels and cigarette smoking or alcohol consumption. There was also no significant correlation between the level of serum estrone and any of the lipid or apoprotein measures. However, estradioi concentration was significantly correlated with apo A-l (rho=0.20, p=0.02). The correlation of estradioi with HDL 2 c was of borderline significance (rho=0.15, p=0.07).
The levels of HDLc, HDL 2 c, and triglycerides were significantly different among the quintiles of estradioi (Table 2 ). There were no significant differences for any of the lipoproteins or apoproteins between the quintiles of estrone (Table 3) .
The relationship between estradioi and HDLc and HDL 2 c was not linear (see the means in Table 2 ). The highest quintile of estradioi differed from the other four quintiles in a direction consistent with a biological effect of estradioi. The total cholesterol and LDLc levels were lower, and the HDLc and HDL 2 c levels were higher for women in the highest quintile of estradioi. The mean HDLc was 55.7 mg/dl for women in the lowest four quintiles and 65.0 mg/dl for women in the highest quintile (p=0.02, nonparametric one-way analysis of variance). The mean HDL 2 c was 15.7 mg/dl for women in the four lowest quintiles and 25.1 mg/dl for those in the highest quintile (p=0.002). The mean LDLc was 128.6 mg/dl for those in the four lowest quintiles and 114.5 mg/dl for women in the highest quintile (p=0.14). The mean BMI was 26.8 for those in the four lowest quintiles and 23.7 among women in the highest quintile, and the waist-to-hip ratio was 0.77 for those in the four lowest quintiles and 0.72 for women in the highest quintile. Overall, women in the highest quintile of estradioi had higher HDLc and HDL 2 c, and lower LDLc, total cholesterol, triglycerides, and apo B than women in the lower four quintiles. The lack of a linear relationship between estradioi and lipoprotein levels could be due to withinindividual variability of estradioi or possibly to a threshold effect of level of estradioi.
We have attempted to further evaluate the relationship between relatively high estradioi and estrone levels and lipoproteins and apoproteins. We measured free estradioi levels by using equilibrium dialysis methods. The correlation between total and free estradioi was extremely high See the legend to Table 2 for an explanation of the abbreviations.
(0.85), and only 2% of the total estradiol was free. There were no consistent differences in the results with free estradiol values as compared with those with total estradiol. The multiple regression analysis included other determinants of HDLc, HDL 2 c, and LDLc. Our results showed both BMI and waist-to-hip ratio to be inversely related to HDLc and HDL 2 c (Table 4) , and the waist-to-hip ratio to be directly related to LDLc. Age was significantly and negatively related to HDL 2 c. The regression coefficient for estradiol in the equation predicting HDL 2 c was not significant but was in the same direction (positive) as the univariate comparison in Table 2 . The univariate and multivariate relationships of estrone with HDL 2 c levels were similar. Values of estradiol are pg/ml. Other values are mg/dl. See the legend to Table 2 for an explanation of the abbreviations.
Table 5. Comparison of Changes in Lipoprotein and Apoprotein Levels for Women in Highest Quintile of Estradiol at First Postmenopausal Examination with Women in Remaining Four Quintiles
Changes in hormones and lipoproteins over time were also evaluated. To date, 39 women have had repeat estradiol measures and 52 women have had repeat estrone measures at the second annual postmenopausal visit, approximately 1 year after the initial postmenopausal exam. Estradiol levels decreased an average of 12.3 pg/ml (SD=22.8, SE=3.7), and estrone decreased 9.8 pg/ml (SD=23.3, SE=3.2). The correlation between estradiol measures 1 year apart was rho=0.10 (p=0.27); for estrone measures, it was rho=0.32 (p=0.009). There were no consistent relationships between changes in estradiol or estrone and changes in lipoprotein levels 1 year later. In the 52 women with repeat estrone measures, their HDLc levels decreased 0.26 mg/dl, HDL 2 c levels decreased 2.5 mg/dl, LDLc increased 2.1 mg/dl, and triglycerides increased 2.7 mg/dl (not shown). The average changes for the 39 women who had repeat estradiol measurements were similar to the total group of 52 women.
In the 10 women whose levels were in the highest quintile at their first postmenopausal examination, estradiol decreased an average of 43.5 pg/ml (Table 5 ). In four of these women, estradiol declined below the level of the sensitivity of the assay (2.5 pg/ml), and for these four women, HDLc decreased 2.6 mg/dl and HDL 2 c declined 6.2 mg/dl. For the remaining six women whose levels remained above the third quintile of estradiol levels, the changes in HDL 2 c were much less (not shown). For the entire sample of 39 women with repeat estradiol measurements, nine (23%) had a decrease in estradiol to below the sensitivity of the assay (Table 6 ). In these nine women, HDL 2 c decreased 4.5 mg/dl, while for the remaining 30 women, HDL 2 c decreased only 1.1 mg/dl. These changes are consistent with an effect of estradiol on HDLc and subtraction levels. The differences in lipoprotein changes between individuals who did or did not have a decrease of estradiol to below the sensitivity of assay were not significant because of the relatively small sample size.
There were 56 postmenopausal women who had undergone a perimenopausal (defined as 3-months' amenorrheic) examination and for whom blood samples had been stored at -70°C. All these women had been followed up carefully after the perimenopausal visit. Some had gone on to become menopausal, and others had remained premenopausal during the study. None were taking hormone replacement therapy or had had an oophorectomy at the time of the perimenopausal visit. Their median estradiol at the perimenopausal exam was Values are mg/dl. *<;2.5 pg/ml. tf test, comparing the nine women to the 30 women. See the legend to Table 2 for an explanation of the abbreviations. Values are pg/ml for estrone and estradiol and mg/dl for all others. LDLc=low density lipoprotein cholesterol, HDLc=high density lipoprotein cholesterol. There were 56 women studied. 30 .35 pg/ml, and their median estrone was 49.9 pg/ml. Estradiol and estrone were highly correlated (Spearman rho=0.91, p=<0.000). Estrone levels were significantly correlated with BMI (rho=0.28, p=0.021). The higher estradiol levels found at the perimenopausal exam as compared to postmenopausal levels are consistent with continued ovarian function during the perimenopause. A high correlation of estrone and estradiol was consistent with a primary ovarian source for both hormones.
Because of the small sample size, we divided the estradiol and estrone levels into tertiles rather than quintiles (Table 7) . Estradiol was <17 pg/ml in the lowest grouping, >17.0 to 64.0 for the middle group, and >64.0 pg/ml in the highest tertile. HDLsC varied from 21.6 mg/dl for those in the lowest tertile to 25.5 mg/dl for those in the highest. The mean LDLc was 131.2 for women in the lowest tertile of estradiol and 118.7 for those in the highest. The differences in HDL 2 c and LDLc between the estrone tertiles were smaller than those for the estradiol tertiles.
Among the 56 perimenopausal women studied, seven have not become menopausal, four have gone on to become postmenopausal but did not have a follow-up visit, three had insufficient blood samples at their postmenopausal examination, three became menopausal after the analysis had been completed, 11 started taking hormone replacement therapy, and 28 became postmenopausal and had repeat hormone studies at both the perimenopausal and first postmenopausal exams. There were no significant differences in the perimenopausal lipoprotein, apoprotein, and hormone levels between the women who did and those who did not have repeat hormone measurements at the first postmenopausal visit.
We evaluated the changes in hormones and lipoproteins between perimenopause and postmenopause for the 28 women who became menopausal and did not take hormone replacement therapy (Table 8 ). Estrone levels decreased 16.5 pg/ml and estradiol, 37.0 pg/ml. The HDL 2 c decreased 5.8 mg/dl and the LDLc increased 2.7 mg/dl. There were no significant correlations between changes in estradiol and changes in lipoprotein levels (not shown). There were seven women whose estradiol levels declined below the level of the sensitivity of the assay (<2.5 pg/ml). HDL 2 c declined an average of 7.5 mg/dl among these seven women as compared to 4.4 mg/dl for the 13 women for whom estradiol levels remained above the level of sensitivity of the assay. There was, however, substantial variability in the change in lipoprotein levels in both groups.
Estrone is the primary postmenopausal hormone. The estrone differences were significantly and inversely correlated with changes in LDLc (rho=-0.39, p=0.02) and changes in total cholesterol (rho=-0.41, p=0.02). Women who maintained relatively high estrone levels from peri-to postmenopause experienced a smaller increase in LDLc. There was no relationship of change in estrone to change in HDLc or subfractions. The levels of Table 2 for an explanation of the abbreviations.
the lipoproteins were all highly and significantly correlated between the perimenopausal and the postmenopausal exams (total HDLc, rho=0.70; HDL 2 c, rho=0.53; LDLc, rho=0.80). The peri-and postmenopausal hormone levels were not significantly correlated (estradiol rho=-0.22, p=0.18, estrone rho=0.28, p=0.08). Perimenopausal hormone levels are primarily determined by ovarian function, while postmenopausal hormone levels are derived from the aromatization of androstenedione to estrone and from estrone to estradiol.
Discussion
Changes in lipoproteins during peri-and postmenopause are due to a combination of aging, hormonal changes, and behavioral factors such as weight gain, exercise, smoking, and alcohol consumption. One of the most interesting and puzzling aspects of the menopause is the relatively small change in HDLc concentration in spite of a marked decline in estradiol levels. The results of analyses of the peri-and postmenopausal women in this study show that the estradiol levels decreased from a median of 30.4 pg/ml at the first perimenopausal visit (3-months amenorrhea), to 8.9 pg/ml at the first postmenopausal visit (12-months amenorrheic) to 5.1 pg/ml at the second postmenopausal visit (24-months amenorrheic). The serum samples were all assayed at the same time; thus, laboratory drift is an unlikely explanation for an overall decline in estradiol level. The estradiol and estrone measurements were assayed without knowledge of the prior hormone levels and, as noted, with careful quality control in the laboratory, including re-analysis of the same control aliquots with each batch of hormone measurements.
Compared to the large decrease in estradiol levels, estrone levels decreased only modestly from a median of 49.9 pg/ml at the perimenopausal visit to a median of 46.8 pg/ml at the initial postmenopausal visit and a median of 38.3 pg/ml at the second postmenopausal visit. We previously reported that women who had become menopausal and were not taking hormone replacement therapy had an average 3 mg/dl decrease in HDLc and a 1.5 mg decrease in HDL 2 c as compared with no decrease in total HDLc and a 0.4 mg/dl increase in HDL 2 c for women who remained premenopausal. LDLc increased 12 mg/dl in the menopausal women and 5.4 mg/dl in those who remained premenopausal. 16 Changes in smoking, alcohol intake, and weight did not account for the decrease in HDL 2 c in the first 3.5 years of follow-up. The only consistent finding from the examination of the relationship of the hormones and lipoprotein levels was a higher HDLc and HDL 2 c and a lower LDLc level among women who were in the highest quintile of estradiol level. A similar, but smaller, association with estrone levels was observed.
We have evaluated the association between hormones and lipoproteins by measuring changes in hormones and lipoprotein levels from the peri-to the initial postmenopausal exam and then to the second postmenopausal exam. The decline in estradiol among women in the highest quintile was accompanied by a substantial fall in HDL 2 c. Both estradiol and HDL 2 c declined substantially from the perimenopausal to the postmenopausal examination, but there was no consistent relationship between change in the estrogen levels and change in any of the other lipoprotein concentrations.
It is difficult to characterize the levels of these hormones during the perimenopausal period because of the rapid decrease in ovarian function. Any attempt, therefore, to correlate change in hormones and lipoproteins may be particularly difficult during the perimenopause except by multiple measurements over relatively short time intervals. Even then, the within-individual variability in hormone levels may be greater than the between-individual variability and may mask a relationship between the hormone and lipoprotein changes.
The postmenopausal women in this study had FSH levels consistent with postmenopausal status. The most likely reason that some of these women had higher estradiol levels was that they continued to have anovulatory cycles early in the climacteric with high estradiol levels unopposed by progesterone. 17 -20 This may have resulted in higher HDLc, HDL 2 c, and apo A-l and lower apo B and LDLc levels relative to women with lower estradiol concentrations. Using the same laboratory, Cauley et al.
14 recently reported that for 176 postmenopausal women (mean age of 58 and 9 years postmenopausal) the mean estrone level was 29.8 pg/ml and that 73% of the women had estradiol levels below the sensitivity of the assay. There was no relationship in those women between hormone and lipoprotein levels. 21 The results of this study do not explain why HDLc declines very little around the time of the menopause and why cross-sectional studies do not show any substantial change in HDLc with increasing age among women. It is possible that total HDLc does not change substantially, but that the relative proportion of HDL 2 c to HDL^c or to other subfractions changes during the menopause. We have previously reported that the primary determinant of postmenopausal estrone is obesity, 14 and the important role of obesity as a major determinant of postmenopausal estrogen level is generally accepted. 22 We have also shown obesity to be associated with increased insulin levels which are, in turn, correlated with lower HDLc and subfractions. 23 The balance, therefore, between levels of sex steroid hormones and insulin and perhaps insulin sensitivity may in part determine the concentration of HDLc and subtractions among postmenopausal women. 24 It is also possible that conversion of estrone to estradiol at the tissue level or the interaction between estradiol and specific receptors and subsequent protein synthesis may be primary factors in determining the levels of HDLc and its subtractions. Measurement of hormone levels in the serum may, therefore, not correlate with lipoproteins, especially in older women. Cauley et al., 25 however, have shown endogenous estrogen blood levels to be related to bone mineral density, suggesting some biological effect of the serum concentrations. Estrogen replacement therapy when given orally raises HDLc and subtractions and lowers LDLc levels. Many liver enzymes and proteins are also increased, probably due to the initial passage of the hormone through the liver. When hormones are given by injection, implantation, or transdermally, the change in HDLc level is much smaller and inconsistent in spite of a substantial increase in blood estradiol level. 26 -30 Clearly, there is not a simple relationship between the estrogen and lipoprotein and apoprotein levels at the time of menopause. The most likely hypothesis based on current data is that high estradiol levels early after menopause are a measure of anovulatory cycles resulting in higher HDLc and, especially, HDL 2 c levels. Estrone derived from the aromatization of androstenedione (an adrenal hormone) is the primary postmenopausal estrogen and maintains the higher HDLc level among postmenopausal women as compared to men. Both estrone and insulin levels are directly related to obesity. Women gain both in weight and percentage of body fat as they get older. 23 The interrelationship between insulin and estrone and possibly the extent of conversion of estrone to estradiol at the tissue level and subsequent activation of protein synthesis may partially determine HDLc level among postmenopausal women and, consequently, the progression of atherosclerosis. It would be of great interest, therefore, to evaluate the relationships between estrogen levels during the peri-and postmenopausal periods, insulin levels and the extent of atherosclerosis, as well as the development of symptomatic atherosclerotic disease. 313233 Finally, if the relationships among sex steroid hormones, insulin, and atherosclerosis can be clarified, then it might be possible to more carefully identify the individual women who are most likely to benefit from postmenopausal hormone replacement therapy for the prevention of cardiovascular disease.
